Diazoxide choline extended-release is the first FDA-approved therapy to address hyperphagia in Prader-Willi syndrome. Soleno Therapeutics announced the medication will be available beginning in April.

The Food and Drug Administration approved a medication this week known as VYKAT XR to treat hyperphagia — or an incessant feeling of hunger — in kids and adults with Prader-Willi syndrome. The ...

Though the exact mechanism of action is unclear, it is believed that in patients with Prader-Willi syndrome, diazoxide choline reduces hyperphagia through activation of the adenosine triphosphate ...

Becoming the first treatment for rare genetic disorder Prader-Willi syndrome, breakthrough therapy drug DCCR (diazoxide choline) gained U.S. FDA approval as Vykat XR the evening before its March 27 ...

The FDA approved extended-release diazoxide choline (Vykat XR) to treat the intense persistent sensation of hunger in patients 4 years of age and older with Prader-Willi syndrome, maker Soleno ...

Soleno Therapeutics' Vykat XR has become the first FDA-approved treatment for Prader-Willi syndrome (PWS), a rare genetic disorder that causes excessive appetite and obesity. Vykat XR (diazoxide ...

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as Vykat XR – to treat extreme hunger in patients with Prader-Willi ...

The US Food and Drug Administration (FDA) has approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release tablets as the first treatment to address hyperphagia in patients with the ...

Shares of Solano Therapeutics are surging after winning US FDA approval for its new drug to treat excessive hunger and people with Prader-Willi syndrome, a genetic disorder that leads to physical ...